Overexpression of human telomerase reverse transcriptase C-terminal polypeptide sensitizes HeLa cells to 5-fluorouracil-induced growth inhibition and apoptosis

Molecular Medicine Reports

Volumn 9, Issue 1, 2014, Pages 279-284

  Lin, Guimiao ^a   Chen, Qiang ^a   Yu, Shuihong ^a   Lin, Suxia ^a   Yao, Hong ^b   Ding, Zhangchi ^a   Chen, Siping ^a   Lin, Marie Chia Mi ^a   Wang, Xiaomei ^a  

^a Shenzhen University School of Medicine   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

5 fluorouracil; Cervical carcinoma; Gene therapy; HTERTC27

Indexed keywords

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 9; CELL PROLIFERATION; FLUOROURACIL; HELA CELLS; HUMANS; PEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; TELOMERASE;

EID: 84893860140     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1777     Document Type: Article

References (25)

1. Markman M: Chemoradiation in the management of cervix cancer: current status and future directions. Oncology 84: 246-250, 2013.
2. Hemaiswarya S and Doble M: Combination of phenylpropanoids with 5-fluorouracil as anti-cancer agents against human cervical cancer (HeLa) cell line. Phytomedicine 20: 151-158, 2013.
3. Yamamoto K, Fujiwara Y, Nishida T, et al: Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. Anticancer Res 29: 4211-4215, 2009.
4. Osaka Y, Shinohara M, Hoshino S, Ogata T, Takagi Y, Tsuchida A and Aoki T: Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res 31: 633-638, 2011.
5. Nagata M, Nakayama H, Tanaka T, et al: Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma. Br J Cancer 105: 1322-1330, 2011.
6. Wang CJ, Stratmann J, Zhou ZG and Sun XF: Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer 10: 616, 2010.
7. Karasawa H, Miura K, Fujibuchi W, et al: Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 100: 903-913, 2009.
8. Lin G, Lin MC, Lin S, et al: Early growth response protein-1 promoter-mediated synergistic antitumor effect of hTERTC27 gene therapy and 5-fluorouracil on nasopharyngeal carcinoma. Cancer Biother Radiopharm 27: 434-441, 2012.
9. Gomez DE, Armando RG, Farina HG, Menna PL, Cerrudo CS, Ghiringhelli PD and Alonso DF: Telomere structure and telomerase in health and disease (Review). Int J Oncol 41: 1561-1569, 2012.
10. Shay JW and Wright WE: Role of telomeres and telomerase in cancer. Semin Cancer Biol 21: 349-353, 2011.
11. Ruden M and Puri N: Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 39: 444-456, 2013.
12. Podlevsky JD and Chen JJ: It all comes together at the ends: telomerase structure, function, and biogenesis. Mutat Res 730: 3-11, 2012.
13. Huang JJ, Lin MC, Bai YX, et al: Ectopic expression of a COOH-terminal fragment of the human telomerase reverse transcriptase leads to telomere dysfunction and reduction of growth and tumorigenicity in HeLa cells. Cancer Res 62: 3226-3232, 2002.
14. Huang J, Bai YX, Han SW, et al: A human TERT C-terminal polypeptide sensitizes HeLa cells to H2O2-induced senescence without affecting telomerase enzymatic activity. Biochem Biophys Res Commun 301: 627-632, 2003.
15. Ng SS, Gao Y, Chau DH, et al: A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. Cancer Gene Ther 14: 561-572, 2007.
16. Gao Y, Ng SS, Chau DH, et al: Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy. Cancer Gene Ther 15: 723-732, 2008.
17. Lin G, Zhao L, Yin F, et al: TCF3 inhibits F9 embryonal carcinoma growth by the down-regulation of Oct4. Oncol Rep 26: 893-899, 2011.
18. Afzal S, Jensen SA, Vainer B, et al: MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol 20: 1660-1666, 2009.
19. Lü MH, Liao ZL, Zhao XY, et al: hTERT-based therapy: A universal anticancer approach (Review). Oncol Rep 28: 1945-1952, 2012.
20. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 35: 495-516, 2007.
21. García-Sáez AJ: The secrets of the Bcl-2 family. Cell Death Differ 19: 1733-1740, 2012.
22. Ola MS, Nawaz M and Ahsan H: Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 351: 41-58, 2011.
23. Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104, 1999.
24. Würstle ML, Laussmann MA and Rehm M: The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. Exp Cell Res 318: 1213-1220, 2012.
25. Rosen A and Casciola-Rosen L: Macromolecular substrates for the ICE-like proteases during apoptosis. J Cell Biochem 64: 50-54, 1997.